Viewing Study NCT06781450


Ignite Creation Date: 2025-12-24 @ 4:48 PM
Ignite Modification Date: 2026-01-01 @ 7:37 PM
Study NCT ID: NCT06781450
Status: RECRUITING
Last Update Posted: 2025-01-30
First Post: 2024-12-03
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Outcomes Module Eligibility Module Contacts Locations Module